Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 3
2012 3
2013 3
2014 2
2015 2
2018 2
2019 3
2020 3
2021 2
2022 2
2023 1
2025 2
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
The following term was not found in PubMed: /
Page 1
ACE inhibitor-mediated angioedema.
Montinaro V, Cicardi M. Montinaro V, et al. Int Immunopharmacol. 2020 Jan;78:106081. doi: 10.1016/j.intimp.2019.106081. Epub 2019 Dec 10. Int Immunopharmacol. 2020. PMID: 31835086 Review.
Angioedema (AE) occurring during ACE inhibitor therapy (ACEi-AE) is a rare complication involving between 0.1 and 0.7% of treated patients. AE can also complicate other therapeutic regimens that block the renin-angiotensin aldosterone system. ...
Angioedema (AE) occurring during ACE inhibitor therapy (ACEi-AE) is a rare complication involving between 0.1 and 0.7% of trea …
Idiopathic Angioedema: Current Challenges.
Belbézier A, Bocquet A, Bouillet L. Belbézier A, et al. J Asthma Allergy. 2020 Apr 17;13:137-144. doi: 10.2147/JAA.S205709. eCollection 2020. J Asthma Allergy. 2020. PMID: 32368100 Free PMC article. Review.
The C1-inhibitor (C1-inh) functional assay can exclude AE due to C1-inh deficiency. Genetic diagnoses of hereditary AE due to abnormal C1-inh AE have progressed with four currently known mutations. However, determining the physiopathological mechanism leading …
The C1-inhibitor (C1-inh) functional assay can exclude AE due to C1-inh deficiency. Genetic diagnoses of hereditary AE due to …
Effect of icatibant on angiotensin-converting enzyme inhibitor-induced angioedema: A meta-analysis of randomized controlled trials.
Jeon J, Lee YJ, Lee SY. Jeon J, et al. J Clin Pharm Ther. 2019 Oct;44(5):685-692. doi: 10.1111/jcpt.12997. Epub 2019 Jul 9. J Clin Pharm Ther. 2019. PMID: 31290163
Icatibant is a bradykinin receptor antagonist approved for hereditary AE treatment. Some recent studies showed a potential role for icatibant on ACEI-induced AE while others have shown no promising effect. This meta-analysis of randomized controlled tr …
Icatibant is a bradykinin receptor antagonist approved for hereditary AE treatment. Some recent studies showed a potential rol …
Efficacy of Treatment of Non-hereditary Angioedema.
van den Elzen M, Go MFCL, Knulst AC, Blankestijn MA, van Os-Medendorp H, Otten HG. van den Elzen M, et al. Clin Rev Allergy Immunol. 2018 Jun;54(3):412-431. doi: 10.1007/s12016-016-8585-0. Clin Rev Allergy Immunol. 2018. PMID: 27672078 Free PMC article.
Therapies were described for angiotensin-converting enzyme inhibitor-induced AE (ACEi-AE), for idiopathic AE, and for AE with wheals. Described treatments consisted of ecallantide, icatibant, C1INH, fresh frozen plasma (FFP), tranexamic acid (TA …
Therapies were described for angiotensin-converting enzyme inhibitor-induced AE (ACEi-AE), for idiopathic AE, and for …
[Drug induced angioedema (ACE-inhibitors and other)].
Fain O, Mekinian A, Gobert D, Khau CA, Javaud N. Fain O, et al. Presse Med. 2015 Jan;44(1):43-7. doi: 10.1016/j.lpm.2014.07.019. Epub 2014 Dec 12. Presse Med. 2015. PMID: 25511647 Review. French.
ACE-I AE must be treated as in the hereditary form when life threatening signs are present, with icatibant or C1 inhibitor concentrate. AE can occur in 10% of angiotensin receptor blockers (ARBs) treated patients who had developed ACE-I AE....
ACE-I AE must be treated as in the hereditary form when life threatening signs are present, with icatibant or C1 inhibitor con …
Icatibant , the bradykinin B2 receptor antagonist with target to the interconnected kinin systems.
Charignon D, Späth P, Martin L, Drouet C. Charignon D, et al. Expert Opin Pharmacother. 2012 Oct;13(15):2233-47. doi: 10.1517/14656566.2012.723692. Epub 2012 Sep 13. Expert Opin Pharmacother. 2012. PMID: 22970904 Review.
Icatibant is registered for the treatment of acute attacks of the hereditary BK-mediated AE, i.e., AE due to C1 inhibitor deficiency. ...It underlines the responsibility of the kinins in AE initiation and the potency of icatibant to inhibit A …
Icatibant is registered for the treatment of acute attacks of the hereditary BK-mediated AE, i.e., AE due to C1 inhibit …
Recognition and Differential Diagnosis of Hereditary Angioedema in the Emergency Department.
Pines JM, Poarch K, Hughes S. Pines JM, et al. J Emerg Med. 2021 Jan;60(1):35-43. doi: 10.1016/j.jemermed.2020.09.044. Epub 2020 Nov 17. J Emerg Med. 2021. PMID: 33218838 Free article. Review.
While AE is commonly mediated by histamine (allergic AE), some types result from excessive bradykinin activity, including hereditary AE (HAE), acquired AE, and angiotensin-converting enzyme inhibitor-induced AE. ...OBJECTIVE: This review describ …
While AE is commonly mediated by histamine (allergic AE), some types result from excessive bradykinin activity, including here …
Open-label, multicenter study of self-administered icatibant for attacks of hereditary angioedema.
Aberer W, Maurer M, Reshef A, Longhurst H, Kivity S, Bygum A, Caballero T, Bloom B, Nair N, Malbrán A. Aberer W, et al. Allergy. 2014 Mar;69(3):305-14. doi: 10.1111/all.12303. Allergy. 2014. PMID: 24438203 Clinical Trial.
Recurrence or worsening of HAE symptoms (22 of 97) was the most commonly reported AE; rescue medications including icatibant (N = 3) and C1-inhibitor concentrate (N = 6) were used in 13 cases. ...The median time to symptom relief (3.8 h) was comparable with results …
Recurrence or worsening of HAE symptoms (22 of 97) was the most commonly reported AE; rescue medications including icatibant ( …
[Bradykinin mediated angioedema].
Bouillet L, Boccon-Gibod I, Massot C. Bouillet L, et al. Rev Med Interne. 2011 Apr;32(4):225-31. doi: 10.1016/j.revmed.2009.11.021. Epub 2010 Jun 9. Rev Med Interne. 2011. PMID: 20538389 French.
Skin or mucous membranes (upper respiratory and intestinal) could be affected. Bradykinin AE can be secondary to: (1) AE associated with C1 inhibitor deficiency (hereditary or acquired); (2) drug-induced AE (converting enzyme inhibitors ); (3) type III AE …
Skin or mucous membranes (upper respiratory and intestinal) could be affected. Bradykinin AE can be secondary to: (1) AE assoc …
Angioedema: etiology, pathophysiology, current and emerging therapies.
Lewis LM. Lewis LM. J Emerg Med. 2013 Nov;45(5):789-96. doi: 10.1016/j.jemermed.2013.03.045. Epub 2013 Aug 29. J Emerg Med. 2013. PMID: 23992848 Review.
Life-threatening airway swelling can also occur. AE may be allergic or nonallergic. The overall lifetime incidence of AE is reported to be as high as 15%. ...Thus, although current therapeutic options for ACEi-AE are limited, recent advances in the treatment …
Life-threatening airway swelling can also occur. AE may be allergic or nonallergic. The overall lifetime incidence of AE is re …
24 results